Interaction between phenobarbital and thioridazine

Area of Science:

• Pharmacology
• Neuroscience
• Clinical Pharmacy

Background:

• Antiepileptic drugs (AEDs) like phenobarbital (PB) and phenytoin (PHT) are crucial for managing epilepsy.
• Drug interactions can alter AED efficacy and patient safety, necessitating careful monitoring.
• Thioridazine (TDZ), an antipsychotic, has potential for interactions with other medications.

Purpose of the Study:

• To investigate the impact of thioridazine (TDZ) on serum levels of phenobarbital (PB) and phenytoin (PHT) in individuals with intellectual disabilities.
• To determine if TDZ alters the steady-state serum concentrations of PB and PHT when co-administered.

Main Methods:

• A case-control study design was employed, matching individuals on TDZ with controls receiving only AEDs.
• Participants were matched based on age, sex, body weight, and AED dosage.
• Trough, steady-state serum levels of PB and PHT were measured during routine monitoring.

Main Results:

• Concomitant administration of TDZ (100-200 mg/day) resulted in significantly lower serum PB levels per unit dose compared to PB alone.
• The observed reduction in PB levels appeared to be responsive to the TDZ dosage.
• Thioridazine (TDZ) did not demonstrate consistent effects on serum PHT levels.

Conclusions:

• Thioridazine (TDZ) exhibits a dose-dependent interaction that reduces serum phenobarbital (PB) levels.
• Clinicians should be aware of this interaction when prescribing TDZ concurrently with PB.
• Further research may be warranted to elucidate the mechanism of this interaction and its clinical implications for PHT.